Established in 2023, Ollin Biosciences™ is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases. With a differentiated pipeline, world-class team, and strong investor syndicate, Ollin is redefining what's possible in ophthalmology.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
07/01/26	$330,000,000	Series B	Andreessen Horowitz ARCH Venture Partners Blackstone Canada Pension Plan Investment Board Commodore Capital Monograph Capital Mubadala Capital RA Capital Management T. Rowe Price Associates TCGX	undisclosed